Keirsten Montgomery
Family · Mount Vernon, WANPI 1023261492
Payments from drug & device makers
Across 699 payments — averaging $20.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- Amgen$2K
- Novo Nordisk$1K
- AstraZeneca$757
- Mannkind Corporation$718
- Bigfoot Biomedical Inc$678
- plus $7K from 37 others
What the payments were for
- Travel & lodging$90%
- Food & beverage$14,231100%
- Education$340%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,274 in reported general payments places this provider in the 95th percentile of 1,706 family providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 333 | $466,157 |
| MounjaroTirzepatide | 187 | $249,161 |
| TrulicityDulaglutide | 143 | $198,732 |
| JardianceEmpagliflozin | 125 | $160,876 |
| FarxigaDapagliflozin Propanediol | 145 | $150,433 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 120 | $107,951 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $39,291 |
| RybelsusSemaglutide | 29 | $34,955 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 27 | $34,008 |
| TymlosAbaloparatide | 13 | $34,004 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 36 | $33,718 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 37 | $31,637 |
| Humalog Kwikpen U-100Insulin Lispro | 74 | $24,395 |
| TradjentaLinagliptin | 15 | $18,881 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 134 | $15,442 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,183 | $504,861380 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $2,215 | $460,766375 claims |
| Boehringer IngelheimJardiance, Tradjenta | $347 | $179,757140 claims |
| AstraZenecaFarxiga | $757 | $150,433145 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $645 | $36,79341 claims |
| Radius Health, Inc.Tymlos | $285 | $34,00413 claims |
| MerckJanuvia, Steglatro | $85 | $21,38325 claims |
| AbbVieSynthroid | $564 | $9,41088 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,706 family providers in Washington.
Other family in Mount Vernon
- Jessica WilcoxMount Vernon$7K
- Patric SchineCentralia$842K
- Sharla PetersonKenmore$192K
- Zelda SwainSpokane$83K
- Savannah MorganRenton$76K
- Kevan PettersonSeattle$56K
- Kelly McFeeSunnyside$42K
- Cheryl SomersSpokane$31K
- Hye-Jin GehringBellevue$30K
- Kaitlin BrasierSeattle$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.